semaglutide compounding lawsuit FDA ignites new fight over copycat GLP-1 weight loss drugs Hims is in the crosshairs.

Description

Patients using semaglutide for diabetes who also seek weight loss can discuss with their provider whether pursuing higher doses is appropriate for their specific situation

Obesity increases the risk of a variety of other chronic diseases, including type 2 diabetes, heart disease, and certain cancers

The lawsuit explains that the drug makers knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis. But their failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate. Eli Lilly and Co

[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Angarita G.A., Matuskey D., Pittman B., Costeines J.L., Potenza M.N., Jastreboff A.M., Schmidt H.D., Malison R.T

A study published in The New England Journal of Medicine in February 2021 focusing on the use of semaglutide (sold as Ozempic, Wegovy, and Rybelsus) for weight loss showed that people lost an average of 6.9 kg (or about 15.2 pounds) of body weight at the end of 40 weeks